Frederick Frank is Chairman of EVOLUTION Life Sciences Partners (ELSP). He is also Co-founder and Managing Partner of Life Sciences Partners, LLC, a financial advisory firm. Before joining ELSP, Mr. Frank was Chairman of Burrill Securities and Vice Chairman of Burrill & Company. He began his investment banking career at Smith, Barney & Co. in 1958, where he attained the positions of Co-head of Research, Vice President, and Director. In 1969, he joined Lehman Brothers as a partner and eventually became Vice Chairman. At Lehman Brothers, Frank provided investment banking services to numerous companies in the pharmaceutical, biotechnology, healthcare services, medical device, and nutraceutical industries, and was involved in hundreds of financings, strategic alliances, and merger and acquisition transactions in the global healthcare industry. Mr. Frank was also Vice Chairman at both Barclays Capital and Peter J. Solomon Company.
Mr. Frank’s clients included Marion Laboratories, from leading the company’s initial public offering to its acquisition of the pharmaceutical division of Dow Chemical, creating Marion Merrill Dow. Together with Mary Tanner, Frank represented Marion Merrill Dow in its merger with Hoechst to form Hoechst Marion Roussel. Frank also represented Synthélabo in France in its acquisition by Sanofi, and Genentech, commencing in 1995, with the purchase of a controlling interest by Roche and in its 1999 extension & modification. He advised CV Therapeutics in its $l.4 billion sale to Gilead Sciences; BioDuro, a China-based company, in its sale to PPD; TargeGen, in its sale to Sanofi-Aventis, CGI Pharmaceuticals, in its sale to Gilead Sciences; and OSI Pharmaceuticals in its sale to Astellas Pharma.
Mr. Frank is a Senior Advisor to PureTech Ventures; Director at Landec Corporation and a former Director and current Advisor to the Board of PDL BioPharma; a Director Emeritus at the Institute For Systems Biology, a member of the board of the Life Sciences Foundation; a past Director of the Salk Institute; a member of the Yale School of Organization and Management Advisory Board, Chairman, a member of the Pharmaceutical Executive Magazine advisory board and The Journal of Life Sciences, the former Chairman of the Board of The Irvington Institute for Immunological Research, a member of the Advisory Board of The Harvard School of Public Health and also a past member of the Advisory Board of the Johns Hopkins’ Bloomberg School of Public Health, and he served on the Advisory Board of the Massachusetts Institute of Technology Center for Biomedical Innovation. He is past President of the Board of the The Hotchkiss School, and currently serves as a Trustee Emeritus. Frank received an M.B.A. from Stanford University and a B.A. from Yale University. He is also a chartered financial analyst.
Mr. Frank was honored for Outstanding Contributions in the Field of Immunology in 1998 by the Irvington Institute for Immunological Research, and, in 1997, he received the Biotech Meeting at Laguna Niguel Hall of Fame Award for Special Recognition for an Individual. He received The Albert Einstein Award from the Weizmann Institute of Science in 2004, the 2006 Gilda’s Club of New York City Visionary Award and was selected The Top 100 Living Contributors to Biotechnology by Reed Elsevier and in 2007 he received the Award for Excellence from the American Liver Foundation.